TumorSight Viz

K231130

SimBioSys, Inc. · cleared 2023-12-26 · product code QIH · Radiology

FDA 510(k) summary for TumorSight Viz (K231130)

Constat organizes this clearance into predicate context, validation evidence, reported performance, postmarket signals, and reimbursement links. Each extracted claim stays tied to the public FDA source; missing fields remain explicitly unstated.

Validation studies
1
Cited predicates
1
Performance observations
2
Product code
QIH

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.4)
“The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer.”
Algorithmdeep learning algorithm for segmentation
source quote (p.7)
“The measurements generated from the device result directly from the segmentation methodology and are an inferred reflection of the performance of the deep learning algorithm.”
Adaptive (vs locked)FDA source did not state this
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (1)

Reader study (MRMC)

n=163 cases · 6 site(s)

endpoints: tumor volume; tumor-to-breast volume ratio; tumor longest dimension; tumor-to-nipple distance; tumor-to-skin distance; tumor-to-chest distance; tumor center of mass; Dice coefficient; distance between the centers of mass

standards: ISO 14971

Reported performance (2 observations)

diceas written: “Volume Dice”0.676CI ± 0.289
source quote (p.8)
“Volume Dice 0.676 ± 0.289”
diceas written: “Surface Dice”0.873CI ± 0.264
source quote (p.8)
“Surface Dice 0.873 ± 0.264”

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

1
recalls in product code, 24mo
4
MAUDE reports in code, 12mo
—
vs code's own 3-yr baseline
3
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K251766 (decision 2025-07-08) from SimBioSys, Inc. for a matching device line ("TumorSight Viz") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K251766

  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K243189 (decision 2024-10-25) from SimBioSys, Inc. for a matching device line ("TumorSight Viz") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K243189

  • recall_reason_pattern

    Software/algorithm-related recall in product code QIH (PIE Medical Imaging B.V., initiated 2026-05-07): "User measurement value reported by diagnostic bioimaging software intended to measure/visualize cardiovascular structures may be larger (0.8% to 34.4%) than the actual anatomical d" Recalling firm is another firm in the same product code.

    first seen 2026-08-26 · recall res_event_number:98930

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device); a recall is shown as device-attributed only when the recall record itself lists this clearance number. Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-08-26.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

Applicable FDA guidance — what the submission is measured against

FDA guidance documents and guiding principles applicable to 510(k) AI/ML devices in the Radiology panel. A curated reference index, not legal or regulatory advice — each item states its own status, and a draft is never binding.

Applicability is derived from the device's FDA advisory panel and pathway — cross-cutting guidances apply to every AI/ML device; panel-specific ones are flagged. Titles, dates, and links verified against fda.gov as of July 2026.

Related FDA clearances

These are recent clearances in the same FDA product-code category. Shared classification does not by itself make a device an appropriate predicate.

Constat Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: constat.dev/precedent/device/K231130